Lucinda Y. Quan - Jul 7, 2022 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role: Executive Vice President, Chief Business Officer and General Counsel
Signature: /s/ Lucinda Y. Quan
Stock symbol: ALGS
Transactions as of: Jul 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/11/2022, 04:15 PM
Previous filing: Feb 8, 2022
Next filing: Mar 17, 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALGS	Stock Option (Right to Buy)	Award	$0	+52.5K		$0.00	52.5K	Jul 7, 2022	Common Stock	52.5K	$1.41	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Executive Vice President, Chief Business Officer and General Counsel